NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has acquired Trek Diagnostic Systems from Magellan Biosciences for an undisclosed amount.
Trek makes blood culture, microorganism identification, and antibiotic-susceptibility testing products for the pharmaceutical and clinical lab markets. The firm is based near Cleveland, has 150 employees, and had full-year 2010 revenues of $34 million.
"The range of products manufactured by Trek ideally complements our existing portfolio of microbiological testing technologies," Thermo Fisher President and CEO Marc Casper said in a statement.
Trek will be integrated into Thermo Fisher's Analytical Technologies segment.
The acquisition is the latest in a string for Thermo Fisher. The firm is in the process of acquiring allergy and autoimmune diagnostics firm Phadia for $3.5 billion, and it recently purchased chromatography firm Dionex for $2.1 billion.